AR079324A1 - Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindazol - Google Patents

Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindazol

Info

Publication number
AR079324A1
AR079324A1 ARP100104528A ARP100104528A AR079324A1 AR 079324 A1 AR079324 A1 AR 079324A1 AR P100104528 A ARP100104528 A AR P100104528A AR P100104528 A ARP100104528 A AR P100104528A AR 079324 A1 AR079324 A1 AR 079324A1
Authority
AR
Argentina
Prior art keywords
compounds
compound
formula
azaindazol
indazol
Prior art date
Application number
ARP100104528A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan T Reeves
Hossein Razavi
Sonia Rodriguez
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR079324A1 publication Critical patent/AR079324A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
ARP100104528A 2009-12-08 2010-12-07 Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindazol AR079324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26753809P 2009-12-08 2009-12-08

Publications (1)

Publication Number Publication Date
AR079324A1 true AR079324A1 (es) 2012-01-18

Family

ID=43416915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104528A AR079324A1 (es) 2009-12-08 2010-12-07 Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindazol

Country Status (17)

Country Link
US (1) US20110137042A1 (OSRAM)
EP (1) EP2509952A1 (OSRAM)
JP (1) JP2013512954A (OSRAM)
KR (1) KR20120101667A (OSRAM)
CN (1) CN102596908A (OSRAM)
AR (1) AR079324A1 (OSRAM)
AU (1) AU2010328480A1 (OSRAM)
BR (1) BR112012013582A2 (OSRAM)
CA (1) CA2782384A1 (OSRAM)
CL (1) CL2012001300A1 (OSRAM)
EA (1) EA201200820A1 (OSRAM)
IL (1) IL219274A0 (OSRAM)
IN (1) IN2012DN05081A (OSRAM)
MX (1) MX2012006524A (OSRAM)
PH (1) PH12012501153A1 (OSRAM)
TW (1) TW201144282A (OSRAM)
WO (1) WO2011071730A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
EP2346868B1 (en) 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists
MX2012004644A (es) 2009-10-21 2012-05-08 Boehringer Ingelheim Int Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1.
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしてのピラゾロピペリジン化合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
WO1994001415A1 (fr) * 1992-07-03 1994-01-20 Kumiai Chemical Industry Co., Ltd. Derive heterocyclique condense et desherbant
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
KR950702555A (ko) * 1993-06-25 1995-07-29 모치츠키 노부히코 인다졸술포닐요소 유도체, 그의 용도 및 제조 중간체(indazolesulfonylurea derivative, its use and intermediate for its production)
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
GB9519563D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
GB9615449D0 (en) * 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
KR20010031783A (ko) * 1997-11-04 2001-04-16 데이비드 존 우드 Pde4 억제제 중 인다졸에 의한 카테콜의 생등입체성치환을 기재로 하는 치료상 활성인 화합물
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
WO2001000656A2 (en) * 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2465207C (en) * 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
TW200406385A (en) * 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
ES2436606T3 (es) * 2003-03-12 2014-01-03 Celgene Corporation Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7371757B2 (en) * 2003-08-15 2008-05-13 Astrazeneca Ab Fused heterocycles as inhibitors of glutamate racemase(MURI)
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
AU2006224568A1 (en) * 2005-03-16 2006-09-21 Basf Aktiengesellschaft Biphenyl-N-(4-pyridyl) methylsufonamides
PL1881823T3 (pl) * 2005-05-17 2015-05-29 Sarcode Bioscience Inc Kompozycje i sposoby leczenia chorób oczu
PT1924561E (pt) * 2005-09-01 2013-01-16 Lilly Co Eli Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados
WO2007102883A2 (en) * 2005-10-25 2007-09-13 Smithkline Beecham Corporation Chemical compounds
KR20080104351A (ko) * 2006-03-31 2008-12-02 노파르티스 아게 유기 화합물
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
CA2699631A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone compounds and p2x7 receptor inhibitors
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
EP2346868B1 (en) * 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists

Also Published As

Publication number Publication date
IN2012DN05081A (OSRAM) 2015-10-09
PH12012501153A1 (en) 2012-10-22
AU2010328480A1 (en) 2012-05-17
EP2509952A1 (en) 2012-10-17
CA2782384A1 (en) 2011-06-16
IL219274A0 (en) 2012-06-28
JP2013512954A (ja) 2013-04-18
TW201144282A (en) 2011-12-16
MX2012006524A (es) 2012-07-17
KR20120101667A (ko) 2012-09-14
CN102596908A (zh) 2012-07-18
EA201200820A1 (ru) 2013-01-30
BR112012013582A2 (pt) 2016-07-05
CL2012001300A1 (es) 2012-09-07
WO2011071730A1 (en) 2011-06-16
US20110137042A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
AR079324A1 (es) Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindazol
PE20110858A1 (es) Procesos para preparar inhibidores de jak y compuestos intermediarios relacionados
EA201270550A1 (ru) Процесс получения соединений для применения в качестве ингибиторов sglt2
EA201490616A1 (ru) Использование ацилсульфонамидов для улучшения урожайности растений
AR072447A1 (es) Proceso para preparar 2- alcoximetilen-4,4-difluoro-3-oxobutiratos de alquilo
PE20100487A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
MX2013000773A (es) Procedimiento de preparacion de derivados de amino-benzoil-benzofu rano.
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
RU2012116208A (ru) Способ получения n-ацилбифенилаланина
AR078916A1 (es) Procedimiento para la purificacion de paliperidona
NZ601040A (en) Method of producing acrylic and methacrylic acid
RU2012102669A (ru) Способ получения соединений, являющихся производными кетомалоновой кислоты, или их гидратов
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
PE20120223A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
RU2012157539A (ru) Способ получения кристаллической 3,6,9- триаза-3,6.9- трис-( карбоксиметил) -4-(4-этоксибензил) ундекановой дикислоты и ее применение для получения примовиста®
PE20130252A1 (es) Intermedios de agomelatina y metodo de preparacion de estos
AR073807A1 (es) Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
ES2657424T3 (es) Procedimiento de preparación de 1-alquil-3-difluorometil-5-fluor-1H-pirazol-4-carbaldehídos y 1-alquil-3-difluorometil-5-fluor-1H-pirazol-4-carboxilatos
AR075441A1 (es) Un proceso para la preparacion de etoricoxib
RU2007141562A (ru) Способ получения пероксида водорода
SI1940772T1 (sl) Nov postopek za pripravo kvarternih amonijevih soli kislin
AR094240A1 (es) Proceso para producir cristal de compuesto de pirazol
MY181791A (en) Process for the preparation of propionic acid derivatives
WO2014062221A1 (en) Aryl tetrafluorosulfanyl compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure